GoodRx (NASDAQ:GDRX) Price Target Cut to $8.50 by Analysts at UBS Group

GoodRx (NASDAQ:GDRX) had its target price decreased by stock analysts at UBS Group from $9.00 to $8.50 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. UBS Group’s price objective indicates a potential upside of 19.89% from the stock’s current price.

Other equities research analysts have also recently issued reports about the stock. Royal Bank of Canada upgraded shares of GoodRx from a “sector perform” rating to an “outperform” rating and increased their target price for the company from $8.00 to $10.00 in a research report on Thursday, May 23rd. Barclays boosted their target price on GoodRx from $9.00 to $10.00 and gave the company an “overweight” rating in a research report on Monday, May 20th. Raymond James raised GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a research report on Friday. TD Cowen increased their target price on shares of GoodRx from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, May 16th. Finally, Morgan Stanley upped their price objective on GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a research report on Monday, June 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, GoodRx has an average rating of “Moderate Buy” and a consensus price target of $9.34.

GoodRx Stock Performance

Shares of NASDAQ:GDRX traded up $0.08 on Friday, hitting $7.09. 1,183,287 shares of the company were exchanged, compared to its average volume of 1,457,823. GoodRx has a 1-year low of $4.14 and a 1-year high of $9.26. The firm has a market capitalization of $2.66 billion, a P/E ratio of -709.00, a price-to-earnings-growth ratio of 4.08 and a beta of 1.39. The company has a current ratio of 6.29, a quick ratio of 6.29 and a debt-to-equity ratio of 1.02. The stock’s 50 day moving average price is $8.29 and its 200 day moving average price is $7.37.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Thursday, May 9th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The business had revenue of $197.88 million for the quarter, compared to analyst estimates of $196.20 million. GoodRx had a negative net margin of 0.86% and a positive return on equity of 3.45%. Sell-side analysts predict that GoodRx will post 0.17 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Beacon Capital Management LLC bought a new stake in GoodRx in the 1st quarter valued at about $28,000. Plato Investment Management Ltd acquired a new stake in shares of GoodRx in the second quarter valued at about $43,000. Gerber LLC bought a new position in shares of GoodRx in the fourth quarter worth about $75,000. Schnieders Capital Management LLC acquired a new position in shares of GoodRx during the 1st quarter worth about $93,000. Finally, Innealta Capital LLC bought a new stake in GoodRx during the 4th quarter valued at approximately $91,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.